文献速递系统性红斑狼疮

阿尼鲁单抗对系统性红斑狼疮患者报告结局的长期影响(TULIP-LTE):一项随机、安慰剂对照、3期长期扩展试验

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.
PubMed 文献 · Lancet Rheumatol · 2025-05-02

TULIP-LTE是一项3期随机双盲安慰剂对照长期扩展试验,评估阿尼鲁单抗300 mg每4周一次对369例接受标准治疗的中重度SLE患者患者报告结局的影响。4年治疗期间两组患者报告结局评分均较基线改善,阿尼鲁单抗组在SF-36v2(急性版)躯体疼痛和精神健康领域及SF-6D的改善在数值上高于安慰剂组。作者认为这些数值改善伴随疾病活动度改善、糖皮质激素剂量减少和可耐受的安全性特征。

要点

  • 4年治疗期间两组患者报告结局评分均较基线改善。
  • 第208周时阿尼鲁单抗组SF-36v2躯体疼痛最小二乘均值差5.9(95%CI -0.7至12.5),精神健康3.7(95%CI -1.2至8.6)。
  • SF-6D改善阿尼鲁单抗组普遍大于安慰剂组,第24周起可见数值差异并维持至第208周。

核心结论

  • 4年治疗期间患者报告健康状况和健康相关生活质量改善,包括数值上偏向阿尼鲁单抗的差异。
  • 作者认为这些患者报告结局的数值改善与疾病活动度改善、糖皮质激素剂量减少和可耐受的安全性特征同时出现。
  • 作者提示这些数据表明阿尼鲁单抗是一种可能改善健康相关生活质量的有效治疗选择。

研究设计与样本

  • TULIP-LTE是1年TULIP-1和TULIP-2试验的3年随机、双盲、安慰剂对照、3期长期扩展试验。
  • 分析纳入在TULIP-1和TULIP-2中随机接受阿尼鲁单抗300 mg(n=257)或安慰剂(n=112)每4周一次并在TULIP-LTE中继续相同治疗的患者。
  • 2016年6月30日至2018年10月12日期间369例患者进入长期扩展研究并纳入此项探索性分析(阿尼鲁单抗组257例,安慰剂组112例)。
  • 所有分析在改良意向治疗人群中进行,该人群包括TULIP-1和TULIP-2中所有随机分配且在长期扩展阶段接受至少一剂相同治疗的患者。
  • 患者报告结局最小二乘均值评分采用重复测量模型校正。

主要发现

  • 患者平均年龄42.8岁(SD 11.5),369例患者中340例(92%)为女性、29例(8%)为男性,250例(68%)为白人、82例(22%)自认为西班牙裔或拉丁裔。
  • 第208周时SF-36v2(急性版)躯体疼痛领域最小二乘均值差5.9(95%CI -0.7至12.5)、精神健康领域3.7(95%CI -1.2至8.6),阿尼鲁单抗组数值上高于安慰剂组。
  • SF-6D从基线的改善阿尼鲁单抗组普遍大于安慰剂组,第24周即见组间数值差异(最小二乘均值差0.013 [95%CI -0.007至0.032])并维持至第208周(0.016 [95%CI -0.010至0.042])。

关键数值与推荐

  • 探索性终点为患者报告结局(SF-36v2急性版、患者疾病活动度整体评估、EQ-5D-5L、狼疮工作生产力和活动受损量表)及源自SF-36v2(急性版)和EQ-5D-5L的健康效用指数SF-6D从基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the TULIP-1 and TULIP-2 phase 3 trials, anifrolumab treatment was associated with clinical efficacy and clinically meaningful improvements in multiple patient-reported outcomes over 52 weeks in patients with moderate-to-severe systemic lupus erythematosus (SLE). At the end of TULIP-1 and TULIP-2 (week 52), eligible patients could reconsent to enter a 3-year long-term extension trial (TULIP-LTE). Here, we investigated changes in patient-reported outcomes during treatment with anifrolumab or placebo for up to 4 years in patients with SLE who were receiving standard therapy. METHODS: TULIP-LTE was a 3-year randomised, double-blind, placebo-controlled, phase 3 long-term extension of the 1-year TULIP-1 and TULIP-2 trials. Patients who were randomly assigned to receive anifrolumab 300 mg (n=257) or placebo (n=112) every 4 weeks in the TULIP-1 and TULIP-2 trials and who continued the same treatment in TULIP-LTE were assessed. Exploratory endpoints were changes from baseline in patient-reported outcomes (Short Form-36 version 2 acute recall [SF-36v2 (acute)], Patient Global Assessment of disease activity, EuroQoL 5 Dimensions-5 Levels [EQ-5D-5L], and Work Productivity and Activity Impairment-Lupus) and health utility indices, Short-Form 6-Dimension (SF-6D), derived from SF-36v2 (acute), and EQ-5D-5L. All analyses were done in the modified intention-to-treat population, which included all randomly assigned patients from TULIP-1 and TULIP-2 who received at least one dose of the same treatment during the long-term extension phase. Least-squares mean patient-reported outcome scores were adjusted using a repeated measures model. No people with lived experience were directly involved in the study design or implementation. This trial was registered with ClinicalTrials.gov, NCT02794285. FINDINGS: Between June 30, 2016, and Oct 12, 2018, 369 patients entered the long-term extension study and were included in this exploratory analysis (257 in the anifrolumab group and 112 in the placebo group). Mean age of patients was 42·8 years (SD 11·5), 340 (92%) of 369 patients were women and 29 (8%) were men, 250 (68%) patients were White and 82 (22%) self-identified as Hispanic or Latino. Patient-reported outcome scores improved from baseline in both groups during the 4-year treatment period. At week 208, improvement from baseline in SF-36v2 (acute) was numerically higher in the anifrolumab group than the placebo group for the bodily pain domain (least-squares mean difference 5·9 [95% CI -0·7 to 12·5]) and the mental health domain (3·7 [-1·2 to 8·6]). Improvements from baseline in SF-6D were generally greater in the anifrolumab group than the placebo group, with numerical differences between groups evident from as early as week 24 (least-squares mean difference 0·013 [-0·007 to 0·032]) and maintained at week 208 (0·016 [-0·010 to 0·042]). INTERPRETATION: Over 4 years of treatment, patients reported improvements in health status and health-related quality of life, including differences favouring anifrolumab compared with placebo. These numerical improvements in patient-reported outcomes occurred alongside improvements in disease activity, reduced glucocorticoid doses, and a tolerable safety profile. These data suggest that anifrolumab is an effective treatment option that might improve health-related quality of life. FUNDING: AstraZeneca.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Strand V, Kalunian KC, Lee KW, et al. Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial. Lancet Rheumatol. 2025. PMID: 40324450. doi:10.1016/S2665-9913(25)00022-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。